Cite
MLA Citation
V. Tirunagaru et al.. “Combination of MDM2 inhibition with milademetan and MEK inhibition leads to improved anti-tumor activity in cancer models harboring WT TP53.” European journal of cancer, vol. 174, n.d., pp. S20–S21. http://access.bl.uk/ark:/81055/vdc_100168600408.0x000041